A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity
Conditions
Obesity · Overweight
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Parexel International GmbH, Berlin, Germany
Study leads
Clinical Transparency (dept. 2834)
Study Director
Novo Nordisk A/S